ClinicalTrials.gg
CompletedNCT02573870Updated Jul 21, 2020Results posted

Batefenterol/Fluticasone Furoate in Treatment of Chronic Obstructive Pulmonary Disease

A Phase 2 interventional study of Batefenterol + Fluticasone Furoate and Placebo in Pulmonary Disease, Chronic Obstructive, sponsored by GlaxoSmithKline. Completed at 10 sites in United States. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2020-07-21.

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
63
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing batefenterol in Pulmonary Disease, Chronic Obstructive — none open to participants now, none under way, none of them phase 3. batefenterol · Pulmonary Disease, Chronic Obstructive.

Enrollment
4th of 10
63 · median 47
Started
2015
with 1 other
Phase 2
4 of 10
none open now
Registered
9th of 10
by date
Lead sponsor
6 of 10
GlaxoSmithKline

Among the 10 studies testing batefenterol in Pulmonary Disease, Chronic Obstructive, this one is the 4th largest by enrollment, is one of 2 that started in 2015, is one of 4 in phase 2, and was the 9th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

None of the 10 studies testing batefenterol in Pulmonary Disease, Chronic Obstructive is open now. The open studies under Pulmonary Disease, Chronic Obstructive, anywhere →

About batefenterol

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing batefenterol in Pulmonary Disease, Chronic Obstructive as a file.
02

Study summary

Batefenterol inhalation powder is currently under development as a fixed-dose combination with fluticasone furoate (FF) for the treatment of Chronic Obstructive Pulmonary Disease (COPD).

The present study will administer batefenterol/FF (300/100 micrograms [mcg]) for the first time to subjects with COPD, to investigate the safety and tolerability of the combination compared with placebo, and to evaluate the pharmacokinetics and pharmacodynamics profiles of the individual components when administered in combination.

This is a Phase IIa, multicenter, randomized, placebo-controlled, double-blind, parallel group study. Subjects will be randomized (2:1) to one of the following double-blind treatment groups:

Batefenterol/FF 300/100 mcg inhalation powder once daily, or matching placebo inhalation powder once daily.

Subjects will self-administer the study treatments once daily (QD) in the morning for 42 days via a multi-dose dry powder inhaler (DPI) which contains two blister strips. Additionally, an inhaled short acting beta2-receptor agonist, albuterol will be provided from screening to the end of the treatment period for all subjects to use as needed to relieve COPD symptoms. At the end of the treatment period, subjects can resume conventional therapy.

The study will randomize approximately 60 subjects. The total duration of subject participation (from screening to follow-up) will be approximately 8 weeks.

03

Conditions studied

  • Pulmonary Disease, Chronic Obstructive

Keywords

  • COPD
  • DPI
  • Batefenterol
  • Fluticasone Furoate
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Type of subject: Outpatient.
  • : Capable of giving signed informed consent, which includes compliance with pre-specified requirements and restrictions.
  • Age and gender: Male and female subjects, 40 years of age or older at the time of signing the informed consent, are eligible to participate in the study.

Female subject: is eligible to participate if she is not pregnant (as confirmed by a negative urine human chorionic gonadotrophin (hCG) test), not lactating, and at least one of the following conditions applies:

  1. Non- defined as:

    Pre-menopausal females with one of the following: documented tubal ligation; documented hysteroscopic tubal occlusion procedure with follow-up confirmation of bilateral tubal occlusion; hysterectomy; documented bilateral oophorectomy defined as 12 months of spontaneous amenorrhea. Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the highly effective methods if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of post-menopausal status prior to study enrolment.

  2. Reproductive potential and agrees to follow one of the options listed below 30 days prior to the first dose of study medication and until at least five terminal half-lives OR until any continuing pharmacologic effect has ended, whichever is longer after the last dose of study medication and completion of the follow-up visit. This list does not apply to females of reproductive potential with same sex partners, when this is their preferred and usual lifestyle or for subjects who are and will continue to be abstinent from penile-vaginal intercourse on a long term and persistent basis:

Contraceptive subdermal implant that meets the standard operating procedure (SOP) effectiveness criteria including a \<1% rate of failure per year, as stated in the product label Intrauterine device or intrauterine system that meets the SOP effectiveness criteria including a \<1% rate of failure per year, as stated in the product label Oral Contraceptive, either combined or progestogen alone Injectable progestogen Contraceptive vaginal ring Percutaneous contraceptive patches Male partner sterilization with documentation of azoospermia prior to the female subject's entry into the study, and this male is the sole partner for that subject These allowed methods of contraception are only effective when used consistently, correctly and in accordance with the product label. The investigator is responsible for ensuring that subjects understand how to properly use these methods of contraception.

  • (COPD): An established clinical history of COPD in accordance with the definition by the American Thoracic Society/European Respiratory Society.
  • COPD Disease severity: A post-albuterol (FEV1)/forced vital capacity (FVC) ratio of =\<0.70 and a post-albuterol FEV1 >=30 and =\<80% of predicted normal values calculated using the European Respiratory Society Global Lung Function Initiative reference equations at Visit 1.
  • Smoking history: Current or former cigarette smokers with a history of cigarette smoking of >= 10 pack-years at Visit 1. Former smokers are defined as those who have stopped smoking for at least 6 months prior to Visit 1.

Number of pack years = (number of cigarettes per day / 20) x number of years smoked (for example, 20 cigarettes per day for 10 years, or 10 cigarettes per day for 20 years both equal 10 pack-years).

Note: Pipe and cigar use cannot be used to calculate pack-year history.

Exclusion criteria

Exclusion Criteria:

  • Asthma: A current diagnosis of asthma (Subjects with a prior history of asthma are eligible if they have a current diagnosis of ).
  • Other Respiratory Disorders: Known alpha-1 antitrypsin deficiency, active lung infections (such as tuberculosis), and lung cancer are absolute exclusionary conditions. Other excluded conditions include and not limited to bronchiectasis, pulmonary hypertension unrelated to COPD, sarcoidosis, or interstitial lung disease. Or a subject who, in the opinion of the investigator, has any other significant respiratory conditions in addition to COPD
  • Other Diseases/Abnormalities: Subjects with historical or current evidence of clinically significant cardiovascular, neurological, psychiatric, renal, hepatic, immunological, endocrine (including uncontrolled diabetes or thyroid disease) or hematological abnormalities that are uncontrolled and/or a previous history of cancer in remission for \<5 years prior to Visit 1 (localized carcinoma of the skin that has been resected for cure is not exclusionary). Significant is defined as any disease that, in the opinion of the investigator, would put the safety of the subject at risk through participation, or which would affect the efficacy or safety analysis if the disease/condition exacerbated during the study.
  • Poorly controlled COPD: defined as the occurrence of 'acute worsening of COPD that is managed with and/or antibiotics or that requires treatment prescribed by a physician in the 6 weeks prior to Screening (Visit 1)', or 'subjects who are hospitalized due to acute worsening of COPD within 12 weeks of Visit 1'.
  • History of COPD exacerbation: subject who have had more than one exacerbation (moderate or severe) within the 12 months prior to Visit 1.
  • Pneumonia and lower respiratory tract infection: Subjects with lower respiratory tract infection that required the use of antibiotics within 6 weeks prior to Visit 1; or subjects hospitalized due to pneumonia within 12 weeks of Visit 1.
  • Use of long-term oxygen therapy (LTOT): Oxygen therapy prescribed for greater than 12 hours a day. As-needed oxygen use (that is, =\<12 hours per day) is not exclusionary.
  • Nebulized Therapy: Regular use (prescribed for use every day, not for as-needed use) of short-acting bronchodilators (for example, albuterol) via nebulized therapy.
  • Lung Resection: Lung volume reduction surgery within the 12 months prior to Visit 1.
  • Clinically significant abnormal laboratory finding at Visit 1.
  • Liver Disease: Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
  • Presence of surface antigen (HBsAg), or positive antibody test result at screening. Subjects with positive Hepatitis C antibody due to prior resolved disease can be enrolled, only if a confirmatory negative Hepatitis C ribonucleic acid polymerase chain reaction test is obtained.
  • Abnormal and clinically significant findings from 12-lead (ECG) performed at Visit 1. Site investigators will be provided with ECG over-read conducted by a centralized independent cardiologist, to assist in evaluation of subject eligibility. For this study, an abnormal and clinically significant ECG that would preclude a subject from entering the trial is defined as a 12-lead tracing that is interpreted as, but not limited to, any of the following:

Sinus bradycardia \<45 beats per minute (bpm) (Note: Sinus bradycardia \<45 bpm should be confirmed by two additional readings at least 5 minutes apart) Sinus tachycardia >=110 bpm (Note: Sinus tachycardia >=110 should be confirmed by two additional readings at least 5 minutes apart) Multifocal atrial tachycardia (wandering atrial pacemaker with rate >100 bpm) PR interval >240 milliseconds (msec) Evidence of Mobitz II second degree or third degree atrioventricular (AV) block Pathological Q waves (defined as wide [>0.04 seconds] and deep [>0.4 millivolt (mV) (4 millimeters [mm] with 10 mm/mV setting)] or >25% of the height of the corresponding R wave, providing the R wave was >0.5 mV [5 mm with 10 mm/mV setting], appearing in at least two contiguous leads (Note: prior evidence [that is, ECG obtained at least 12 months prior) of pathological Q waves that are unchanged are not exclusionary; and the investigator will determine if the subject is precluded from entering the study) Evidence of ventricular ectopic couplets, bigeminy, trigeminy or multifocal premature ventricular complexes.

For subjects without complete right bundle branch block: corrected by Fridericia's method (QTc[F]) >=450 msec or an ECG that is unsuitable for QT measurements (for example, poor defined termination of the T wave) For subjects with complete right bundle branch block: QTc(F) >=480msec or an ECG that is unsuitable for QT measurements (for example, poor defined termination of the T wave) (Note: All potentially exclusionary QT measurements should be confirmed by two additional readings at least 5 minutes apart) ST-T wave abnormalities (excluding non-specific ST-T wave abnormalities) (Note: prior evidence (that is, ECG obtained at least 12 months prior) of ST-T waves that are unchanged are not exclusionary and the investigator will determine if the subject is precluded from entering the study) Clinically significant conduction abnormalities (for example, Wolff-Parkinson-White syndrome or bifascicular block defined as complete left bundle branch block or complete right bundle branch block with concomitant left fascicular block) Clinically significant arrhythmias (for example, atrial fibrillation with rapid ventricular response, ventricular tachycardia)

  • Medication Prior to Spirometry: Unable to withhold albuterol for the 4 hour period required prior to spirometry testing at each study visit.
  • Excluded Medications: Use of the following medications are not permitted within the defined time intervals prior to Visit 1 and throughout the study:

Depot corticosteroids: 12 weeks Systemic, oral or parenteral corticosteroids: 6 weeks Antibiotics (for lower respiratory tract infection): 6 weeks 'Cytochrome P450 3A4' strong inhibitors and 'P-glycoprotein' inhibitor: 4 weeks Long acting beta-agonist (LABA)/inhaled corticosteroid (ICS) combination products : 4 weeks ICS : 4 weeks Phosphodiesterase 4 (PDE4) inhibitors (roflumilast): 1 week LABA/ Long-acting muscarinic antagonist (LAMA) combination (for example, vilanterol/umeclidinium bromide): 1 week Once-daily beta2-agonist (for example, Olodaterol and Indacaterol): 1 week LAMA (tiotropium, aclidinium, glycopyrronium, umeclidinium): 1 week Theophylline preparations: 48 hours Oral leukotriene inhibitors (zafirlukast, montelukast, zileuton): 48 hours Oral beta2-agonists Long-acting: 48 hours Short-acting: 12 hours Inhaled LABA (for example, Salmeterol, formoterol): 48 hours Inhaled sodium cromoglycate or nedocromil sodium: 24 hours Inhaled short acting beta2-agonists: 4 hours Inhaled short-acting anticholinergics: 4 hours Inhaled short-acting anticholinergic/short-acting beta2-agonist combination products: 4 hours Use of study provided albuterol is permitted during the study, except in the 4-hour period prior to spirometry testing

  • Drug or Alcohol Abuse: A known or suspected history of alcohol or drug abuse within 2 years prior to Visit 1.
  • : Any history of allergy or to any anticholinergic/muscarinic receptor antagonist, beta-2-agonist, sympathomimetic, corticosteroid (intranasal, inhaled or systemic) lactose/milk protein, or a medical condition such as narrow-angle glaucoma, prostatic hypertrophy or bladder neck obstruction, that, in the opinion of the study physician contraindicates study participation or use of an inhaled LAMA, LABA or ICS
  • The subject has participated in a clinical trial and has received an product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer)
  • Affiliation with Investigator Site: A subject will not be eligible for this study if he/she is an immediate family member of the participating investigator, sub-investigator, study coordinator, or employee of the participating investigator.
  • Inability to read: In the opinion of the investigator, any subject who is unable to read and/or would not be able to complete a diary.
  • Questionable validity of consent: Subjects with a history of psychiatric disease, intellectual deficiency, poor motivation or other conditions that will limit the validity of to participate in the study.
  • Non-compliance: Subjects at risk of non-compliance, or unable to comply with the study procedures. Any infirmity, disability, or geographic location that would limit compliance for scheduled visits.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
63 participants (actual)

Study arms

  • Experimental
    Batefenterol + Fluticasone Furoate

    Subjects will self-administer batefenterol/fluticasone furoate 300/100 micrograms inhalation powder once daily for 42 days. Albuterol will be provided from screening to Day 42, to use as needed for symptom relief.

    Drug: Batefenterol + Fluticasone Furoate · Drug: Albuterol

  • Placebo comparator
    Placebo

    Subjects will self-administer matching placebo inhalation powder once daily for 42 days. Albuterol will be provided from screening to Day 42, to use as needed for symptom relief.

    Drug: Placebo · Drug: Albuterol

Interventions

  • DrugBatefenterol + Fluticasone Furoate

    Drug pages: Batefenterol · Fluticasone furoate

    Batefenterol and Fluticasone Furoate (FF) will be provided as a fixed-dose combination in a dry powder inhaler (DPI), for oral inhalation once every morning, for 42 days. The DPI will consist of 2 strips of 30 blisters each, containing 300 microgram (mcg) batefenterol per blister in one strip and 100 mcg FF per blister in another strip. Both drugs will be available in a micronized form, blended with lactose monohydrate.

  • DrugPlacebo

    Placebo will be provided in a DPI, for oral inhalation once every morning, for 42 days. The DPI will consist of 2 matching strips of 30 blisters each, with each blister containing lactose monohydrate and no active pharmaceutical ingredient.

  • Albuterol inhalation will be provided as an open-label rescue medication to use as needed, to relieve chronic obstructive pulmonary disease (COPD) symptoms.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in 0 to 4 Hours Post-dose Weighted Mean Heart Rate at Day 42, Derived From Electrocardiograms (ECGs)

    ECG measurements were taken in supine position after obtaining vital signs. Weighted mean was derived by calculating the area under the curve (AUC), and then dividing by the relevant time interval. Baseline was the pre-dose measurement on Day 1. Change from Baseline in 0 to 4 hours post-dose weighted mean heart rate was measured on Days 1, 28 and 42 and was analyzed using a mixed models repeated measures (MMRM) model. Intent-To-Treat (ITT) Population: all randomized participants who received at least one dose of study medication.

    Time frame: Baseline and Day 42

07

Results

Posted Mar 28, 2017

Participant flow

This study consisted of 1-week run-in period, 6-week (42-day) treatment period and 1-week follow-up period. Eligible participants (par.) were randomized (2:1) to either batefenterol (BAT)/fluticasone furoate (FF) 300/100 micrograms (µg) or a placebo in double blinded treatment.

Participant flow — Overall Study
MilestonePlaceboBAT/FF 300/100 µg
Started2042
Completed2035
Not completed07
Withdrew: Adverse event02
Withdrew: Lack of efficacy01
Withdrew: Other: reached defined stopping criteria01
Withdrew: Lost to follow-up01
Withdrew: Other: fail to meet visit02

Outcome measures

PrimaryChange From Baseline in 0 to 4 Hours Post-dose Weighted Mean Heart Rate at Day 42, Derived From Electrocardiograms (ECGs)

ECG measurements were taken in supine position after obtaining vital signs. Weighted mean was derived by calculating the area under the curve (AUC), and then dividing by the relevant time interval. Baseline was the pre-dose measurement on Day 1. Change from Baseline in 0 to 4 hours post-dose weighted mean heart rate was measured on Days 1, 28 and 42 and was analyzed using a mixed models repeated measures (MMRM) model. Intent-To-Treat (ITT) Population: all randomized participants who received at least one dose of study medication.

Time frame:
Baseline and Day 42
Reported as:
Least squares mean · Beats per minute (bpm)
Change From Baseline in 0 to 4 Hours Post-dose Weighted Mean Heart Rate at Day 42, Derived From Electrocardiograms (ECGs)
Beats per minute (bpm)PlaceboBAT/FF 300/100 µg
Change From Baseline in 0 to 4 Hours Post-dose Weighted Mean Heart Rate at Day 42, Derived From Electrocardiograms (ECGs)0.688 ± 1.5238-1.557 ± 1.1374
Statistical analysis
  • Placebo vs BAT/FF 300/100 µg · Mean difference (final values): -2.245 · 95% CI -6.153 to 1.663Treatment difference is calculated as active minus placebo and the non-inferiority bound was 10 bpm for Day 42

Adverse events

Collected over Serious Adverse Events (SAEs) were collected from start of the study until the follow-up contact (Visit 7 [Visit 6/EW +7 days]). Non-serious AEs were collected from the start of study treatment (Visit 2) until the follow-up contact (Visit 7). Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—0/20 (0%)7/20 (35%)
BAT/FF 300/100 µg—0/42 (0%)8/42 (19%)
Most frequent other events
Showing 10 of 14
Most frequent other events
EventPlaceboBAT/FF 300/100 µg
DysgeusiaNervous system disorders0/204/42
DiarrhoeaGastrointestinal disorders0/203/42
NasopharyngitisInfections and infestations1/203/42
VertigoEar and labyrinth disorders1/200/42
NauseaGastrointestinal disorders1/200/42
FatigueGeneral disorders1/200/42
SinusitisInfections and infestations1/201/42
Candida infectionInfections and infestations1/200/42
Blood pressure increasedInvestigations1/200/42
Back painMusculoskeletal and connective tissue disorders1/200/42

Baseline characteristics

Age, Continuous
Age, Continuous(Years)PlaceboBAT/FF 300/100 µgTotal
Mean61.4 ± 8.8663.0 ± 7.8862.5 ± 8.17
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboBAT/FF 300/100 µgTotal
Female122436
Male81826
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboBAT/FF 300/100 µgTotal
African American/African Heritage347
American Indian or Alaskan Native101
White - Arabic/North African Heritage022
White - White/Caucasian/European Heritage163652
08

Study locations

10 sites
  • GSK Investigational Site
    Phoenix, Arizona 85006, United States
  • GSK Investigational Site
    Hollywood, Florida 33021, United States
  • GSK Investigational Site
    Baltimore, Maryland 21225, United States
  • GSK Investigational Site
    Charlotte, North Carolina 28207, United States
  • GSK Investigational Site
    Gastonia, North Carolina 28054, United States
  • GSK Investigational Site
    Grove City, Ohio 43123, United States
  • GSK Investigational Site
    Easley, South Carolina 29640, United States
  • GSK Investigational Site
    Mount Pleasant, South Carolina 29464, United States
  • GSK Investigational Site
    Seneca, South Carolina 29678, United States
  • GSK Investigational Site
    McKinney, Texas 75069, United States
09

References and documents

Publications

  • Crim C, Gotfried M, Spangenthal S, Watkins M, Emmett A, Crawford C, Baidoo C, Castro-Santamaria R. A randomized, controlled, repeat-dose study of batefenterol/fluticasone furoate compared with placebo in the treatment of COPD. BMC Pulm Med. 2020 May 4;20(1):119. doi: 10.1186/s12890-020-1153-7. PubMed 32366249 ↗

Individual participant data

Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD is available via the Clinical Study Data Request site (click on the link provided below)

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Data sharing details ↗ · clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2015 to primary completion in Jul 2016, 7 months.

Results were first posted in Mar 2017, 8 months after primary completion.

Of 118 industry-sponsored phase 2 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 20. This study's 7 months is below that.

Counting every sponsor, half of 165 studies reached it within 17 months; a quarter within 10 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 8, 2015
First posted
Oct 12, 2015
StartActual
Dec 1, 2015
Primary completionActual
Jul 5, 2016
CompletionActual
Jul 5, 2016
Results first posted
Mar 28, 2017
Last update
Jul 21, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 21, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02573870
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Oct 12, 2015
Start date
Dec 1, 2015
Primary completion
Jul 5, 2016
Completion
Jul 5, 2016
Results posted
Mar 28, 2017
Last update
Jul 21, 2020

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Batefenterol · Fluticasone furoate

Start the discussion